Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Cited by (1,000)

Items 101–200 of 1,000

1. Non-canonical functions of the RB protein in cancer
   Frederick A. Dick, David W. Goodrich, Julien Sage, Nicholas J. Dyson · 2018 · Nature reviews. Cancer
2. Kinase Domain Mutations in Cancer: Implications for Small Molecule Drug Design Strategies
   Jack Andrew Bikker, Natasja Brooijmans, Allan Wissner, Tarek S. Mansour · 2009 · Journal of Medicinal Chemistry
3. <i>In vitro</i> modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant <i>EGFR</i> mutants in non-small-cell lung cancer
   Hirano, Toshiyuki, Yasuda, Hiroyuki, Tani, Tetsuo, Hamamoto, Junko, Oashi, Ayano, Ishioka, Kota, Arai, Daisuke, Nukaga, Shigenari, Miyawaki, Masayoshi, Kawada, Ichiro et al. · 2015 · Oncotarget
4. Development of EGFR-Targeted Polymer Blend Nanocarriers for Combination Paclitaxel/Lonidamine Delivery To Treat Multi-Drug Resistance in Human Breast and Ovarian Tumor Cells
   Lara Scheherazade Milane, Zhenfeng Duan, Mansoor M. Amiji · 2010 · Molecular Pharmaceutics
5. EGFR mutations are detected comparably in cytologic and surgical pathology specimens of nonsmall cell lung cancer
   Jason H. Smouse, Edmund S. Cibas, Pasi Antero Janne, Victoria A. Joshi, Kelly H. Zou, Neal Ian Lindeman · 2009 · Cancer Cytopathology
6. EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story
   Lecia Van Dam Sequist, Thomas James Lynch · 2007 · Annual Review of Medicine
7. Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity
   Lee, Steve C., Srivastava, Raghvendra M., López-Albaitero, Andrés, Ferrone, Soldano, Ferris, Robert L. · 2011 · Immunologic Research
8. Hsp90 Inhibition Suppresses Mutant EGFR-T790M Signaling and Overcomes Kinase Inhibitor Resistance
   Takeshi Shimamura, Danan Li, Hongbin Ji, Henry J. Haringsma, Elizabeth Liniker, Christa L. Borgman, April M. Lowell, Yuko Minami, Kate L. McNamara, Samanthi A. Perera et al. · 2008 · Cancer Research
9. Superoxide dismutase 1 (SOD1) is a target for a small molecule identified in a screen for inhibitors of the growth of lung adenocarcinoma cell lines
   Romel Somwar, Hediye Erdjument‐Bromage, Erik Larsson, David Shum, William Wirt Lockwood, Guangli Yang, Chris Sander, Ouathek Ouerfelli, Paul Tempst, Hakim Djaballah et al. · 2011 · Proceedings of the National Academy of Sciences
10. Gefitinib and Erlotinib in Metastatic Non-Small Cell Lung Cancer: A Meta-Analysis of Toxicity and Efficacy of Randomized Clinical Trials
    Mauricio Burotto, Elisabet Esteve Manasanch, Julia Wilkerson, Tito Fojo · 2015 · The Oncologist
11. Protein kinase biochemistry and drug discovery
    Phillip A. Schwartz, Brion William Murray · 2011 · Bioorganic Chemistry
12. Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed
    Y. Yosaatmadja, Shevan Silva, James M. J. J. Dickson, Adam Vorn Patterson, Jeff Bruce Smaill, Jack U. Flanagan, Mark James McKeage, Christopher John Squire · 2015 · Journal of Structural Biology
13. Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms
    Toshimitsu Yamaoka, Motoi Ohba, Tohru Ohmori · 2017 · International Journal of Molecular Sciences
14. Exploring Ligand Stability in Protein Crystal Structures Using Binding Pose Metadynamics
    Lucia Fusani, David Scott Palmer, Don O. Somers, Ian D. Wall · 2020 · Journal of Chemical Information and Modeling
15. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer
    Monica Red Brewer, Cai‐Hong Yun, Darson Lai, Mark A. Lemmon, Michael J. Eck, William J. Pao · 2013 · Proceedings of the National Academy of Sciences
16. Protein kinase inhibition of clinically important staurosporine analogues
    Osman A. B. S. M. Gani, Richard Alan Engh · 2010 · Natural Product Reports
17. <i>EGFR</i> Exon 19 Insertions: A New Family of Sensitizing <i>EGFR</i> Mutations in Lung Adenocarcinoma
    He, Mai, Capelletti, Marzia, Nafa, Khedoudja, Yun, Cai-Hong, Arcila, Maria E., Miller, Vincent A., Ginsberg, Michelle S., Zhao, Binsheng, Kris, Mark G., Eck, Michael J. et al. · 2012 · Clinical Cancer Research
18. Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor
    Qingbei Zeng, Jiabing Wang, Ziqiang Cheng, Kan Chen, Peter Johnström, Katarina Varnäs, David Yunzhi Li, Zhen Fan Yang, Xiaolin Zhang · 2015 · Journal of Medicinal Chemistry
19. Uncommon EGFR mutations in advanced non-small cell lung cancer
    Grainne Mary O'Kane, Penelope A. Bradbury, Ronald D. Feld, Natasha B. Leighl, Geoffrey Liu, Katherine-M. Pisters, Suzanne Kamel‐Reid, Ming‐Sound Tsao, Frances A. Shepherd · 2017 · Lung Cancer
20. Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors
    Xiaoyun Lu, Jeff Bruce Smaill, Adam Vorn Patterson, Ke Ding · 2021 · Journal of Medicinal Chemistry
21. Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase Domain
    Nicholas M. Levinson, Steven G. Boxer · 2012 · PLoS ONE
22. Protein Kinase Inhibitor Design by Targeting the Asp-Phe-Gly (DFG) Motif: The Role of the DFG Motif in the Design of Epidermal Growth Factor Receptor Inhibitors
    Yi-Hui Peng, Hui‐Yi Shiao, Chih‐Hsiang Tu, Pang-Min Liu, John T.-A. Hsu, Prashanth K. Amancha, Jian‐Sung Wu, Mohane Selvaraj Coumar, Chun-Hwa Chen, Sing-Yi Wang et al. · 2013 · Journal of Medicinal Chemistry
23. Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor
    Li-Zhi Mi, Chafen Lu, Zongli Li, N. Nishida, Thomas Walz, Timothy A. Springer · 2011 · Nature Structural & Molecular Biology
24. Novel 2-chloro-4-anilino-quinazoline derivatives as EGFR and VEGFR-2 dual inhibitors
    Maria Letícia de Castro Barbosa, Lı́dia Moreira Lima, Roberta Tesch, Carlos Maurício R. Sant’Anna, Frank Totzke, Michael H.G. Kubbutat, Christoph Schächtele, Stefan Laufer, Eliezer J. Barreiro · 2013 · European Journal of Medicinal Chemistry
25. Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
    Rama Krishna Kancha, Nikolas C. C. von Bubnoff, Natalie Bartosch, Christian Peschel, Richard Alan Engh, Justus Duyster · 2011 · PLoS ONE
26. Clinical outcomes in non‐small‐cell lung cancer patients with EGFR mutations: pooled analysis
    Luis G Paz-Ares, Denis Soulières, I. Melezínek, Joachim Moecks, Lorenz Keil, Tony S.K. Mok, Rafael Rosell, Barbara Klughammer · 2010 · Journal of Cellular and Molecular Medicine
27. Computing Clinically Relevant Binding Free Energies of HIV-1 Protease Inhibitors
    David W. Wright, Benjamin A. Hall, Owain A. Kenway, Shantenu Jha, Peter V. Coveney · 2014 · Journal of Chemical Theory and Computation
28. c-Met Inhibitors with Novel Binding Mode Show Activity against Several Hereditary Papillary Renal Cell Carcinoma-related Mutations
    Steven F. Bellon, Paula J. Kaplan‐Lefko, Yajing Yang, Yihong Zhang, Jodi Moriguchi, Karen L. Rex, Carol W. Johnson, Paul Rose, Alexander M. Long, Anne B. O'Connor et al. · 2007 · Journal of Biological Chemistry
29. Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
    Tasia Amelia, Rahmana Emran Kartasasmita, Tomohiko Ohwada, Daryono Hadi Tjahjono · 2022 · Molecules
30. Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor
    Yoshikawa, S, Kukimoto-Niino, M, Parker, L, Handa, N, Terada, T, Fujimoto, T, Terazawa, Y, Wakiyama, M, Sato, M, Sano, S et al. · 2013 · Oncogene
31. Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase
    Thu Ha Truong, Peter M.U. Ung, Prakash B. Palde, Candice E. Paulsen, Avner Schlessinger, Kate S. Carroll · 2016 · Cell chemical biology
32. Rapid Phospho-Turnover by Receptor Tyrosine Kinases Impacts Downstream Signaling and Drug Binding
    Laura B. Kleiman, Thomas Maiwald, H. Conzelmann, Douglas A. Lauffenburger, Peter Karl Sorger · 2011 · Molecular Cell
33. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
    Gang Chen, Peter Kronenberger, Erik Teugels, Ijeoma Adaku Umelo, Jacques De Grève · 2012 · BMC Medicine
34. Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
    Kurtis D. Davies, Sakshi Mahale, David P. Astling, Dara L. Aisner, Anh Tuan Le, Trista K. Hinz, Aria Vaishnavi, Paul A. Bunn, Lynn E. Heasley, Aik Choon Tan et al. · 2013 · PLoS ONE
35. Kinase Inhibitors of Marine Origin
    Sandip Bibishan Bharate, Sanghapal D. Sawant, Parvinder Pal Singh, Ram Ashrey Vishwakarma · 2013 · Chemical Reviews
36. Genomic alterations of ERBB receptors in cancer: clinical implications
    Rosalin Mishra, Ariella B. Hanker, Joan T. Garrett · 2017 · Oncotarget
37. Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers
    Ruth Nussinov, Hyunbum Jang, Chung‐Jung Tsai, Feixiong Cheng · 2019 · PLoS Computational Biology
38. Structural Basis of AZD9291 Selectivity for EGFR T790M
    Xiao-E Yan, Pelin Ayaz, Sujie Zhu, Peng Zhao, Ling Liang, Casey H. Zhang, Ya-Chuang Wu, Je-Luen Li, Hwan Geun Choi, Xin Huang et al. · 2020 · Journal of Medicinal Chemistry
39. Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations
    Littlefield, Peter, Liu, Lijun, Mysore, Venkatesh, Shan, Yibing, Shaw, David E., Jura, Natalia · 2014 · Science Signaling
40. Producing irreversible topoisomerase II-mediated DNA breaks by site-specific Pt(II)-methionine coordination chemistry
    Ying-Ren Wang, Shin-Fu Chen, Chyuan-Chuan Wu, Yi-Wen Liao, Te-Sheng Lin, Ko-Ting Liu, Yi-Song Chen, Tsai‐Kun Li, Tun‐Cheng Chien, Nei‐Li Chan · 2017 · Nucleic Acids Research
41. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
    Michael Juchum, Marcel Günther, Stefan Laufer · 2015 · Drug Resistance Updates
42. Therapeutic progression of quinazolines as targeted chemotherapeutic agents
    Ranju Bansal, Anjleena Malhotra · 2020 · European Journal of Medicinal Chemistry
43. A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization
    Thomas A. Hensing, Apoorva Chawla, Rishi Batra, Ravi Salgia · 2013 · Advances in experimental medicine and biology
44. Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines
    Marc N. Payton, Tammy L. Bush, Grace Chung, Beth Ziegler, Patrick Eden, Patricia L. McElroy, Sandra L. Ross, Victor J. Cee, Holly L. Deak, Brian L. Hodous et al. · 2010 · Cancer Research
45. Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
    Susan E. Jorge, Susumu S. Kobayashi, Daniel Botelho Costa · 2014 · Brazilian Journal of Medical and Biological Research
46. Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition
    Yen, Hsin-Yung, Liu, Ying-Chih, Chen, Nai-Yu, Tsai, Chia-Feng, Wang, Yi-Ting, Chen, Yu-Ju, Hsu, Tsui-Ling, Yang, Pan-Chyr, Wong, Chi-Huey · 2015 · Proceedings of the National Academy of Sciences
47. Discovery of benzimidazole derivatives as novel multi-target EGFR, VEGFR-2 and PDGFR kinase inhibitors
    Yunqi Li, Chunyan Tan, Chunmei Gao, Cunlong Zhang, Xudong Luan, Xiaowu Chen, Hongxia Liu, Yu Chen, Yuyang Jiang · 2011 · Bioorganic & Medicinal Chemistry
48. Induced-fit docking studies of the active and inactive states of protein tyrosine kinases
    Haizhen A. Zhong, Ly M. Tran, Jenna L. Stang · 2009 · Journal of Molecular Graphics and Modelling
49. Targeting Conformational Plasticity of Protein Kinases
    Michael Tong, Markus A. Seeliger · 2014 · ACS Chemical Biology
50. Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization
    Cho, Jeonghee, Chen, Liang, Sangji, Naveen, Okabe, Takafumi, Yonesaka, Kimio, Francis, Joshua M., Flavin, Richard J., Johnson, William, Kwon, Jihyun, Yu, Soyoung et al. · 2013 · Cancer Research
51. Polypharmacology modelling using proteochemometrics (PCM): recent methodological developments, applications to target families, and future prospects
    Isidro Cortés‐Ciriano, Qurrat Ul Ain, Vigneshwari Subramanian, Eelke Bart Lenselink, Oscar Méndez‐Lucio, Adriaan P. IJzerman, Gerd Wohlfahrt, Peteris Prūsis, Thérèse E. Malliavin, Gerard J. P. van Westen et al. · 2014 · MedChemComm
52. Evaluating Caveolin Interactions: Do Proteins Interact with the Caveolin Scaffolding Domain through a Widespread Aromatic Residue-Rich Motif?
    Dominic P. Byrne, Caroline Dart, Daniel John Rigden · 2012 · PLoS ONE
53. A Sensitive Method for Detecting EGFR Mutations in Non-small Cell Lung Cancer Samples with Few Tumor Cells
    Miguel Ángel Molina‐Vila, Jordi Bertrán-Alamillo, Noemı́ Reguart, Miquel Tarón, Eva Castellà, Mariona Llatjós, Carlota Costa, Clara Mayo, Anna Pradas, Cristina Queralt et al. · 2008 · Journal of Thoracic Oncology
54. 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases
    Edgar R. Wood, Lisa M. Shewchuk, Byron Ellis, Perry S. Brignola, Ronald L. Brashear, Thomas R. Caferro, Scott H. Dickerson, Hamilton D. Dickson, Kelly H. Donaldson, Michael D. Gaul et al. · 2008 · Proceedings of the National Academy of Sciences
55. Uncommon Epidermal Growth Factor Receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance
    Massarelli, Erminia, Johnson, Faye M., Erickson, Heidi S., Wistuba, Ignacio I., Papadimitrakopoulou, Vassiliki · 2013 · Lung Cancer
56. ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics
    Nicolas Kiavué, Luc Cabel, Samia Melaabi, Guillaume Bataillon, Céline Callens, Florence Lerebours, Jean‐Yves Pierga, François‐Clément Bidard · 2019 · Oncogene
57. Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer
    Zhendong Song, Ge Yang, Changyuan Wang, Shanshan Huang, Xiaohong H. Shu, Kexin Liu, Youwen Zhou, Xiaodong Ma · 2016 · Journal of Medicinal Chemistry
58. Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC)
    Connor Gerard O’Leary, Harry Michael Gasper, Katherine B. Sahin, Ming Tang, Arutha Kulasinghe, Mark N. Adams, Derek J. Richard, Kenneth John O'Byrne · 2020 · Pharmaceuticals
59. Cancer driver mutations in protein kinase genes
    Ali Torkamani, Gennady M. Verkhivker, Nicholas J. Schork · 2008 · Cancer Letters
60. Cetuximab/C225-Induced Intracellular Trafficking of Epidermal Growth Factor Receptor
    Hong‐Jun Liao, Graham F. Carpenter · 2009 · Cancer Research
61. A Review of the Structure–Activity Relationship of Natural and Synthetic Antimetastatic Compounds
    Su Ki Liew, Sharan Malagobadan, Norhafiza Mohd Arshad, Noor Hasima Nagoor · 2020 · Biomolecules
62. Targeted Therapies for Lung Cancer
    Jill E. Larsen, Tina Cascone, David E. Gerber, John Victor Heymach, John Dorrance Minna · 2011 · The Cancer Journal
63. An Acquired HER2 T798I Gatekeeper Mutation Induces Resistance to Neratinib in a Patient with HER2 Mutant–Driven Breast Cancer
    Ariella B. Hanker, Monica Red Brewer, Jonathan H. Sheehan, James P. Koch, Gregory R. Sliwoski, Rebecca J. Nagy, Richard Burnham Lanman, Michael F. Berger, David Michael Hyman, David B. Solit et al. · 2017 · Cancer Discovery
64. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR , KRAS and ALK gene abnormalities
    Elizabeth Mary Gaughan, Daniel Botelho Costa · 2011 · Therapeutic Advances in Medical Oncology
65. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma
    Silvia Mara Baez Rodriguez, A. El Kamel, Gheorghe Vasile Ciubotaru, Gelu Onose, Ani-Simona Sevastre, Veronica Sfredel, Suzana Dănoiu, Anica Dricu, Ligia Gabriela Tătăranu · 2023 · International Journal of Molecular Sciences
66. TNF-driven adaptive response mediates resistance to EGFR inhibition in lung cancer
    Gong, Ke, Guo, Gao, Gerber, David E., Gao, Boning, Peyton, Michael, Huang, Chun, Minna, John D., Hatanpaa, Kimmo J., Kernstine, Kemp, Cai, Ling et al. · 2018 · Journal of Clinical Investigation
67. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT
    Hsin Hsien Yeh, Kazuma Ogawa, Julius Balatoni, Uday Mukhapadhyay, Asutosh Pal, Carlos González-Lepera, Aleksandr Shavrin, Suren Soghomonyan, Leo G. Flores, Daniel P. Young et al. · 2011 · Proceedings of the National Academy of Sciences
68. Discovery of (<i>R</i>,<i>E</i>)-<i>N</i>-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1<i>H</i>-benzo[<i>d</i>]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers
    Lelais, Gérald, Epple, Robert, Marsilje, Thomas H., Long, Yun O., McNeill, Matthew, Chen, Bei, Lu, Wenshuo, Anumolu, Jaganmohan, Badiger, Sangamesh, Bursulaya, Badry et al. · 2016 · Journal of Medicinal Chemistry
69. Enhanced dimerization drives ligand-independent activity of mutant epidermal growth factor receptor in lung cancer
    Christopher C. Valley, Donna J. Arndt‐Jovin, Narain Karedla, Mara P. Steinkamp, Alexey I. Chizhik, William S. Hlavacek, Bridget Smith Wilson, Keith A. Lidke, Diane S. Lidke · 2015 · Molecular Biology of the Cell
70. Determining EGFR-TKI sensitivity of G719X and other uncommon EGFR mutations in non-small cell lung cancer: Perplexity and solution
    Kaidi Li, Maojun Yang, Naixin Liang, Shanqing Li · 2017 · Oncology Reports
71. Mechanistic insights into the activation of oncogenic forms of EGF receptor
    Zhihong Wang, Patti A. Longo, Mary Katherine Tarrant, Kwangsoo Kim, Sarah A. Head, Daniel J. Leahy, Philip A. Cole · 2011 · Nature Structural & Molecular Biology
72. RETRACTED: Identification of Potent EGFR Inhibitors from TCM Database@Taiwan
    Shun-Chieh Yang, Su‐Sen Chang, Hsin‐Yi Chen, Calvin Yu‐Chian Chen · 2011 · PLoS Computational Biology · Retracted
73. Medicinal attributes of pyridine scaffold as anticancer targeting agents
    Esraa A. Mohamed, Nasser S. M. Ismail, Mohamed Hagras, Hanan M. Refaat · 2021 · Future Journal of Pharmaceutical Sciences
74. Structure and Dynamics of the EGF Receptor as Revealed by Experiments and Simulations and Its Relevance to Non-Small Cell Lung Cancer
    Marisa L. Martin-Fernandez, David T. Clarke, Selene K. Roberts, Laura C. Zanetti-Domingues, Francesco Luigi Gervasio · 2019 · Cells
75. Can EGFR be a therapeutic target in breast cancer?
    Xi‐Yin Li, Lina Zhao, Ceshi Chen, Jianyun Nie, Baowei Jiao · 2022 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
76. Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR
    Anja Michalczyk, Sabine Klüter, Haridas B. Rode, Jeffrey R. Simard, Christian Grütter, Matthias Rabiller, Daniel Rauh · 2008 · Bioorganic & Medicinal Chemistry
77. Orally effective FDA-approved protein kinase targeted covalent inhibitors (TCIs)
    Robert Jr. Roskoski · 2021 · Pharmacological Research
78. The molecular basis of targeting protein kinases in cancer therapeutics
    Chung‐Jung Tsai, Ruth Nussinov · 2013 · Seminars in Cancer Biology
79. Mechanisms of acquired resistance to tyrosine kinase inhibitors
    Yifan Chen, Liwu Fu · 2011 · Acta Pharmaceutica Sinica B
80. Targeting epidermal growth factor receptor: Central signaling kinase in lung cancer
    Takeshi Yoshida, Guolin Zhang, Eric B. Haura · 2010 · Biochemical Pharmacology
81. ‘Latent drivers’ expand the cancer mutational landscape
    Ruth Nussinov, Chung‐Jung Tsai · 2015 · Current Opinion in Structural Biology
82. Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline
    John R. Goffin, Kevin M. Zbuk · 2013 · Clinical Therapeutics
83. Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes
    Adriana Estrada‐Bernal, Anh Tuan Le, Andrea E. Doak, Vijaya G. Tirunagaru, Shevan Silva, Matthew R. Bull, Jeff Bruce Smaill, Adam Vorn Patterson, Chul Kim, Stephen V. Liu et al. · 2020 · Clinical Cancer Research
84. Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6
    Eunyoung Park, Nayoung Kim, Scott B. Ficarro, Yi Zhang, Byung Il Lee, Ahye Cho, Kihong Kim, Angela Kyung-Joo Park, Woong‐Yang Park, Bradley A. Murray et al. · 2015 · Nature Structural & Molecular Biology
85. Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting Epidermal Growth Factor Receptor Threonine790 → Methionine790 Mutant
    Shaohua Chang, Lianwen Zhang, Shilin Xu, Jinfeng Luo, Xiaoyun Lu, Zhang Zhang, Tianfeng Xu, Yingxue Liu, Zhengchao Tu, Yong Xu et al. · 2012 · Journal of Medicinal Chemistry
86. Trisubstituted Imidazoles with a Rigidized Hinge Binding Motif Act As Single Digit nM Inhibitors of Clinically Relevant EGFR L858R/T790M and L858R/T790M/C797S Mutants: An Example of Target Hopping
    Michael Juchum, Marcel Günther, Eva Döring, Adrian Sievers‐Engler, Michael Lämmerhofer, Stefan Laufer · 2017 · Journal of Medicinal Chemistry
87. Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer
    Jasmine Foo, Juliann Chmielecki, William J. Pao, Franziska Michor A · 2012 · Journal of Thoracic Oncology
88. EGF and NRG induce phosphorylation of HER3/ERBB3 by EGFR using distinct oligomeric mechanisms
    Bettina van Lengerich, Christopher Agnew, Elias M. Puchner, Bo Huang, Natalia Jura · 2017 · Proceedings of the National Academy of Sciences
89. Development of Dual Inhibitors Targeting Epidermal Growth Factor Receptor in Cancer Therapy
    Tan, Lun, Zhang, Jifa, Wang, Yuxi, Wang, Xiye, Wang, Yanyan, Zhang, Zhixiong, Shuai, Wen, Wang, Guan, Chen, Juncheng, Wang, Chengdi et al. · 2022 · Journal of Medicinal Chemistry
90. Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies
    Xiang Zhai, Richard A. Ward, Peter C. Doig, Argyrides Argyrou · 2020 · Biochemistry
91. Mechanisms of EGFR Resistance in Glioblastoma
    Peter Pan, Rajiv Magge · 2020 · International Journal of Molecular Sciences
92. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition
    Alexander Christian Backes, Birgit Zech, Béatrice Felber, Bert Klebl, Gerhard Müller · 2008 · Expert Opinion on Drug Discovery
93. Gefitinib Induces Epidermal Growth Factor Receptor Dimers Which Alters the Interaction Characteristics with 125I-EGF
    Hanna Björkelund, Lars Gedda, Pavel Bárta, Magnus Malmqvist, Karl Andersson · 2011 · PLoS ONE
94. Mechanisms for Kinase-mediated Dimerization of the Epidermal Growth Factor Receptor
    Chafen Lu, Li-Zhi Mi, Thomas Schürpf, Thomas Walz, Timothy A. Springer · 2012 · Journal of Biological Chemistry
95. A Multicenter Phase II Study of Erlotinib and Sorafenib in Chemotherapy-Naïve Patients with Advanced Non–Small Cell Lung Cancer
    Joline S.W. Lind, Anne‐Marie C. Dingemans, Harry J.M. Groen, Erik Thunnissen, Otto Bekers, Daniëlle A.M. Heideman, Richard J. Honeywell, Elisa Giovannetti, Godefridus J. Peters, Pieter E. Postmus et al. · 2010 · Clinical Cancer Research
96. Vibrational spectroscopic, molecular docking and density functional theory studies on 2-acetylamino-5-bromo-6-methylpyridine
    Selvarajan Premkumar, T. N. Rekha, R. Mohamed Asath, T. Mathavan, A. Milton Franklin Benial · 2015 · European Journal of Pharmaceutical Sciences
97. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction
    Michael Joe Duffy · 2023 · Tumor Biology
98. Cracking the EGFR code: Cancer biology, resistance mechanisms, and future therapeutic frontiers
    Ya-Fei Du, Feride Karatekin, Wendy Kehan Wang, Wanjin Hong, T. K. B. Gandhi · 2025 · Pharmacological Reviews
99. EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids
    Zhiao Chen, Jinong Feng, J-S Saldivar, Dongqing Gu, Anke Bockholt, Steve S. Sommer · 2008 · Oncogene
100. Sequence and Structure Signatures of Cancer Mutation Hotspots in Protein Kinases
     Anshuman Dixit, Lin Yi, Ragul Gowthaman, Ali Torkamani, Nicholas J. Schork, Gennady M. Verkhivker · 2009 · PLoS ONE